Santhera’s Raxone fails NIH’s MS study in latest setback, shares plunge
Just a few weeks after being shot down (again) by European regulators who were opposed to letting Santhera (SIX: SANN) extend its marketing approval for Raxone to include Duchenne muscular dystrophy, the biotech reported that an early-stage study of the drug failed to demonstrate any value for muscular sclerosis, either.
The NIH ran this study, dividing 77 patients between the drug and a placebo group (66 finished the trial), but found no difference between the two in controlling serious adverse events for patients with a primary progressive form of the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
